Cheilbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 04:21 am
Share
Cheilbio Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 4,101.09 million compared to KRW 5,273.57 million a year ago. Net loss was KRW 539.25 million compared to net income of KRW 173.12 million a year ago. Basic loss per share from continuing operations was KRW 19 compared to basic earnings per share from continuing operations of KRW 6 a year ago. Basic loss per share was KRW 19 compared to basic earnings per share of KRW 6 a year ago.
Cheilbio Co., Ltd. is a Korea-based company engaged in the manufacturing of veterinary drugs. The Company's offerings consist of antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits including enzyme-linked immunosorbent assay (ELISA) test kits, virus test kits and deoxyribonucleic acid (DNA) kits, as well as feed additives. The Companyâs products are used for cattle, pigs, chickens, pets and other animals. It supplies its products mainly to the domestic market.
CHEILBIO CO., LTD. 
